Pivonello Rosario, Faggiano Antongiulio, Lombardi Gaetano, Colao Annamaria
Department of Molecular and Clinical Endocrinology and Oncology, Federico II University, Via Sergio Pansini 5, Naples 80131, Italy.
Endocrinol Metab Clin North Am. 2005 Jun;34(2):327-39, viii. doi: 10.1016/j.ecl.2005.01.010.
Cushing's syndrome (CS) is characterized by a series of systemic complications that increase cardiovascular risk and cause severe atherosclerotic damage that develops in parallel with an acquired metabolic syndrome. Short-term remission from hypercortisolism improves metabolic and vascular damages, but long-term remission from CS seems to be associated with similar or worse metabolic and vascular damage, probably because of persistent abdominal obesity or insulin resistance years after normalization of cortisol secretion. Study results suggest that an increased cardiovascular risk also may persist in patients who undergo treatment with exogenous glucocorticoids after therapy withdrawal. Considering the many patients subjected to corticosteroid treatment, this could be of great clinical relevance and should be investigated thoroughly.
库欣综合征（CS）的特征是一系列全身性并发症，这些并发症会增加心血管风险，并导致严重的动脉粥样硬化损伤，这种损伤与获得性代谢综合征同时发生。高皮质醇血症的短期缓解可改善代谢和血管损伤，但CS的长期缓解似乎与相似或更严重的代谢和血管损伤有关，这可能是由于皮质醇分泌正常化多年后仍存在腹部肥胖或胰岛素抵抗。研究结果表明，在停药后接受外源性糖皮质激素治疗的患者中，心血管风险增加也可能持续存在。鉴于有许多患者接受皮质类固醇治疗，这可能具有重大的临床意义，应进行深入研究。
